Intervention not reported
Atrial fibrillation or flutter, or both (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention may leads to lower atrial fibrillation or flutter, or both (within 30 days) (low certainty).
1 finding from 1 review
Intervention not reported
Bradycardia (within 30 days; as defined by study authors, minimum heart rate < 60 beats per minute or requiring medication) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in bradycardia (within 30 days; as defined by study authors, minimum… (low certainty).
1 finding from 1 review
Intervention not reported
Hypotension (within 30 days; as defined by study authors, minimum systolic blood pressure < 90 mmHg or requiring medication) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in hypotension (within 30 days; as defined by study authors, minimum… (low certainty).
1 finding from 1 review
Early all‐cause mortality (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers showed no clear difference in early all‐cause mortality (within 30 days) compared with placebo or standard care (low certainty).
1 finding from 1 review
Myocardial infarction (0 to 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers may leads to lower acute myocardial infarction (within 30 days) compared with placebo or standard care (low certainty).
1 finding from 1 review
Cerebrovascular events (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers showed no clear difference in cerebrovascular events (within 30 days) compared with placebo or standard care (low certainty).
1 finding from 1 review
Ventricular arrhythmias (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
It is very uncertain whether perioperative beta‐blockers changes ventricular arrhythmias (within 30 days) compared with placebo or standard care (very low certainty).
1 finding from 1 review
Atrial fibrillation or atrial flutter, or both (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers may leads to lower atrial fibrillation or atrial flutter, or both (within 30 days) compared with placebo or standard care (low certainty).
1 finding from 1 review
Bradycardia · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers may leads to higher bradycardia (within 30 days; as defined by study authors, minimum… compared with placebo or standard care (low certainty).
1 finding from 1 review
Hypotension · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers probably leads to higher hypotension (within 30 days; as defined by study authors, minimum… compared with placebo or standard care (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 10‐ to 26‐year‐old males
Three doses HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with control (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with quadrivalent HPV vaccine (moderate certainty).
1 finding from 1 review
Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
The review found no eligible studies for this question.
1 finding from 1 review
Length of stay (inpatients only) · dysphagia in acute and subacute stroke
1 finding from 1 review
All‐cause mortality (within 90 days)
Gelatins showed no clear difference in all‐cause mortality (within 90 days) compared with crystalloid (low certainty).
1 finding from 1 review
All‐cause mortality (within 30 days)
Gelatins showed no clear difference in all‐cause mortality (within 30 days) compared with crystalloid (low certainty).
1 finding from 1 review
All‐cause mortality (within 90 days)
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (within 90 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (at 90 days)
Starches showed no clear difference in all‐cause mortality (at 90 days) compared with crystalloid (moderate certainty).
1 finding from 1 review